Long-term Tumor Control and Late Toxicity in Patients with Prostate Cancer Receiving Hypofractionated (2.2 Gy) Soft-tissue-matched Image-guided Intensity-modulated Radiotherapy.
|Abstract||We report the long-term tumor control and toxicity outcomes of patients undergoing hypofractionated (2.2 Gy) image-guided intensity-modulated radiotherapy (IG-IMRT) using tomotherapy for clinically localized prostate cancer.|
Hypofractionated external beam radiotherapy to boost the prostate with ≥85 Gy/equivalent dose for patients with localised disease at high risk of lymph node involvement: feasibility, tolerance and outcome.
Interfractional Rectal Displacement Requiring Repeated Precaution Did Not Correlate to Biochemical Control and Rectal Toxicity in Patients with Prostate Cancer Treated with Image-guided Intensity-modulated Radiation Therapy.
|Journal Title||anticancer research|
|Publication Year Start||2017-01-01|
PMID- 28982908 OWN - NLM STAT- MEDLINE DCOM- 20171016 LR - 20171016 IS - 1791-7530 (Electronic) IS - 0250-7005 (Linking) VI - 37 IP - 10 DP - 2017 Oct TI - Long-term Tumor Control and Late Toxicity in Patients with Prostate Cancer Receiving Hypofractionated (2.2 Gy) Soft-tissue-matched Image-guided Intensity-modulated Radiotherapy. PG - 5829-5835 AB - AIM: We report the long-term tumor control and toxicity outcomes of patients undergoing hypofractionated (2.2 Gy) image-guided intensity-modulated radiotherapy (IG-IMRT) using tomotherapy for clinically localized prostate cancer. PATIENTS AND METHODS: We examined the cases of 138 consecutive patients with stage T1-T3 prostate cancer that were treated with IG-IMRT from June 2007 to July 2009. The median follow-up time was 79 months (range=31-96 months). The planning target volume received a dose of 72.6-74.8 Gy in 33-34 fractions (2.2 Gy/fraction). Megavoltage computed tomographic (CT) scans were performed before each treatment and corrected to the registered positions on the planning CT scans using prostate soft-tissue matching. RESULTS: The 5-year biochemical and clinical relapse-free survival rates were 95% for the low-risk group, 92% for the intermediate-risk group, and 77% for the high-risk group. The 5-year incidence rates of grade 2 and 3 late gastrointestinal toxicities were 6.3% and 3.1%, respectively, and those of grade 2 and 3 late genitourinary toxicities were 7.9% and 0%, respectively. Multivariate analysis indicated that T-stage is a prognostic factor for biochemical relapse-free survival rates. CONCLUSION: This report involved the longest followed-up cohort of patients to have received hypofractionated (2.2 Gy) soft tissue-matched IG-IMRT using tomotherapy. The findings of this study indicate that hypofractionated IMRT is well tolerated and is associated with good long-term tumor-control outcomes in patients with localized prostate cancer. CI - Copyright(c) 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. FAU - Shimizu, Daisuke AU - Shimizu D AD - Department of Radiology, Kyoto Prefectural University of Medicine, Kyoto, Japan [email protected] FAU - Yamazaki, Hideya AU - Yamazaki H AD - Department of Radiology, Kyoto Prefectural University of Medicine, Kyoto, Japan. FAU - Nishimura, Takuya AU - Nishimura T AD - Department of Radiology, Kyoto first Red Cross Hospital, Kyoto, Japan. FAU - Aibe, Norihiro AU - Aibe N AD - Department of Radiology, Kyoto Prefectural University of Medicine, Kyoto, Japan. FAU - Okabe, Haruumi AU - Okabe H AD - Department of Radiology, Ujitakeda Hospital, Uji, Japan. LA - eng PT - Journal Article PL - Greece TA - Anticancer Res JT - Anticancer research JID - 8102988 SB - IM MH - Adenocarcinoma/diagnostic imaging/pathology/*radiotherapy MH - Disease-Free Survival MH - *Dose Hypofractionation MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Multivariate Analysis MH - Neoplasm Staging MH - Predictive Value of Tests MH - Proportional Hazards Models MH - Prostatic Neoplasms/diagnostic imaging/pathology/*radiotherapy MH - Radiation Injuries/etiology MH - Radiographic Image Interpretation, Computer-Assisted MH - Radiotherapy, Image-Guided/adverse effects/*methods MH - Radiotherapy, Intensity-Modulated/adverse effects/*methods MH - Risk Factors MH - Time Factors MH - Tomography, X-Ray Computed MH - Treatment Outcome OTO - NOTNLM OT - *Tomotherapy OT - *image-guided intensity-modulated radiotherapy OT - *prostate cancer EDAT- 2017/10/07 06:00 MHDA- 2017/10/17 06:00 CRDT- 2017/10/07 06:00 PHST- 2017/07/27 00:00 [received] PHST- 2017/08/16 00:00 [revised] PHST- 2017/08/22 00:00 [accepted] PHST- 2017/10/07 06:00 [entrez] PHST- 2017/10/07 06:00 [pubmed] PHST- 2017/10/17 06:00 [medline] AID - 37/10/5829 [pii] AID - 10.21873/anticanres.12026 [doi] PST - ppublish SO - Anticancer Res. 2017 Oct;37(10):5829-5835. doi: 10.21873/anticanres.12026.